Alunbrig (brigatinib)

Numéro de dossier de l’APP: 21467
État des négociations:
Concluded with an LOI
Indication(s):
For the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) previously untreated with an ALK inhibitor
Promoteur/fabricant:
Takeda Canada Inc.
Numéro de projet de l’ACMTS:
PC0230-000
Lettre-contrat de l’APP:
Conclusion du processus de négociation: